Risk assessment in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-related liver disease: current approaches and future directions
Clinical and Molecular Hepatology · 2026
DOI: 10.3350/cmh.2026.0398 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Huapeng Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, N…. Hauptthemen laut MEDLINE: Fatty Liver, Liver Diseases, Alcoholic, Metabolic Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Abbive, Bristol-Myers Squibb, Gilead Sciences.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol-related liver disease (MetALD) exist on a continuous spectrum in which fibrosis stage remains the dominant predictor of liver‑related complications. Contemporary non‑invasive risk stratification uses simple serum scores (e.g., Fibrosis‑4 index [FIB‑4]) as a first step, followed by vibration‑controlled transient elastography (VCTE) or liver‑specific blood tests (enhanced liver fibrosis [ELF], procollagen III N‑terminal propeptide [PRO‑C3]) to refine risk and triage referrals. Magnetic resonance elastography (MRE) provides higher accuracy than ultrasound‑based elastography, though limited by its availability. Composite models (Agile 3+/4, steatosis‑associated fibrosis estimator [SAFE]) can reduce indeterminate classifications but may require additional calibration for alcohol exposure for use in MetALD. Prognosis should incorporate dynamic, longitudinal measurement of non‑invasive tests, and integrate extrahepatic risks, particularly cardiovascular and kidney disease. In MetALD, quantitative alcohol assessment can be improved by incorporating objective biomarkers such as phosphatidylethanol (PEth) as part of a triangulation approach that integrates self‑reported alcohol intake, the Alcohol Use Disorders Identification Test‑Consumption (AUDIT‑C), and clinical history. Challenges remain, particularly for MetALD, and future research will focus on integrating dynamic biomarkers, predicting treatment response, and utilizing artificial intelligence (AI) for personalized risk and treatment prediction, combining genetic modifiers and polygenic risk scores with clinical and imaging data, with validation across diverse populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Colorectal Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
- Department of Emergency Medicine, The Affiliated JiangNing Hospital of Nanjing Medical University, Nanjing, China.
- Department of Medicine, University of California San Diego, La Jolla, CA, USA.
- State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong. tcfyip@cuhk.edu.hk.
- Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. tcfyip@cuhk.edu.hk.
Förderung
- Abbive
- Bristol-Myers Squibb
- Gilead Sciences
Zitieren
APA
Lin, H., Wang, H., Yang, K., Li, M., Wang, Y., Yip, T. C., & Kim, S. U. (2026). Risk assessment in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-related liver disease: current approaches and future directions. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.0398
Vancouver
Lin H, Wang H, Yang K, Li M, Wang Y, Yip TC, et al. Risk assessment in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-related liver disease: current approaches and future directions. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.0398
BibTeX
@article{Lin2026,
author = {Lin, Huapeng and Wang, Haixia and Yang, Kangsen and Li, Min and Wang, Yanting and Yip, Terry Cheuk-Fung and Kim, Seung Up},
title = {Risk assessment in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-related liver disease: current approaches and future directions},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2026.0398}
}
EUVIMED